Compare iShares MSCI Singapore ETF (EWS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs ResMed Inc. — how do they compare? iShares MSCI Singapore ETF trades at $31.6 (market cap $1.49B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 21.4× iShares MSCI Singapore ETF's market cap, and ResMed Inc. pays a 1.16% dividend while iShares MSCI Singapore ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Singapore ETF for 45 Days and ResMed Inc. for 51 Days on average.
| EWS | RMD | |
|---|---|---|
Market Cap | $1.49B | $31.89B |
Volume | 2,142,305 | 618,314 |
Sector | Broad Market / Factor | Health |
52-Week High | $34.57 | $275.96 |
52-Week Low | $26.71 | $182.82 |
Typical Hold Time | 45 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS (iShares MSCI Singapore ETF) trades at $31.60, down 2.71% with bearish technical signals from moving averages and oscillators. The ETF recently hit 52-week highs amid Singapore's strong economic growth and AI momentum, attracting institutional interest including Amundi's 4.8% position increase. Key support sits at $31 with resistance at $32.
Outlook remains mixed with technical weakness offset by positive fundamental drivers. Investment opportunity lies in Singapore's economic resilience and AI-driven growth, though stretched valuations and bearish momentum present near-term risks. The ETF offers exposure to Asia's outperformance versus S&P 500 but faces volatility from regional economic sensitivity.
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
